| Popis: |
The growing market of pharmaceuticals, dietary supplements, and particularly food products based on live probiotic microorganisms, is evidence of their sufficient prophylactic and, if less marked, therapeutic effects. However, it is currently impossible to precisely determine the optimum quantity of bacteria required for beneficial probiotic effects on human health; in many cases exact data are lacking on probiotic effect mechanisms and targets. It turned out that positive effects of live probiotic microorganisms may be short-term, uncertain or even absent in case of long use. The absence of clear health-promoting effect of prescribed probiotics on the base of live organisms is usually explained by low concentrations of biologically active microbial compounds in places of their application (Reid et al. 2011). In the past few years, experimental and clinical studies have also shown the difficulty, and sometimes even impossibility, of constructing industrially manufactured probiotics for targeted maintaining optimum levels of indigenous microbiota by way of simple selection of a particular live probiotic strain or even their group (Shenderov 2011). |
